BSEBoard Meeting26 Oct 2026 · 26 Oct 2026, 07:48 am
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting scheduled to be held on November 4, 2026 inter alia to consider and approve Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026, and Payment of Interim Dividend, if any, for the financial year 2026-27.
Aurobindo Pharma Ltd · 524804
✦ AI SummaryResults
Aurobindo Pharma Ltd has scheduled a board meeting on November 4, 2026, to consider and approve its second-quarter and half-year unaudited financial results for September 30, 2026, and to consider payment of an interim dividend for the financial year 2026-27.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Aurobindo Pharma Ltd - 524804 - Board Meeting Intimation for Intimation Of Board Meeting
Attachments (1)
📄pdf
Download →
ed83a911-4c69-490e-bbb3-b4c68c62a1a1.pdf
View document text
October 26, 2026
To To
Listing Department, The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED
Exchange Plaza, Phiroz Jeejeebhoy Towers,
Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street,
MUMBAI -400 051 MUMBAI -400 001
Company Code No. AUROPHARMA Company Code No. 524804
Dear Sir/Madam,
Sub: Intimation of Board Meeting.
This is to inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on Wednesday,
November 4, 2026, to consider and approve inter alia, the following:
1. Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year
ended September 30, 2026, and
2. Payment of Interim Dividend, if any, for the financial year 2026-27.
Further to our letter dated September 24, 2026, whereby we informed the closure of Trading Window of the
Company from October 1, 2026, until 48 hours from the date of declaration of the Unaudited Financial Results
of the Company for the second quarter and half year ended September 30, 2026, we inform you that the Trading
Window will remain closed up to November 6, 2026 and shall be re-opened on November 7, 2026.
Please take the information on record.
Thanking you,
Yours faithfully,
For AUROBINDO PHARMA LIMITED
B. Adi Reddy
Company Secretary
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com